Liver-Directed immune therapy shows promise in advanced melanoma
NCT ID NCT04812470
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This early-phase study tested a treatment where a patient's own immune cells (called tumor-infiltrating lymphocytes) are grown in a lab and then infused directly into the liver artery. The goal was to see if this approach is safe and feasible for people with melanoma that has spread to the liver. Eight patients with advanced uveal or cutaneous melanoma took part, and researchers monitored side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Oncology, Sahlgrenska University Hospital
Gothenburg, Sweden
Conditions
Explore the condition pages connected to this study.